Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer

A Complimentary NCPD Symposium Held During the 51st Annual ONS Congress

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

Location

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000

Meeting Room

Grand Ballroom A-F (Third Floor)

No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.

Faculty

Blanca Ledezma

Faculty

Blanca Ledezma

MSN, NP, AOCNP

Department of Hematology Oncology Santa Monica, California

UCLA Health

Marissa Marti-Smith

Faculty

Marissa Marti-Smith

DNP, APRN, AGNP-C, AOCNP

Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, Texas

Nurse Practitioner

Ruth M O'Regan, MD

Faculty

Ruth M O'Regan, MD

University of Rochester Medical Center, Rochester, New York

Charles A Dewey Professor of Medicine and Oncology, Chair, Department of Medicine,

Strong Memorial Hospital, Rochester, New York

Physician-in-Chief

Wilmot Cancer Institute, Rochester, New York

Associate Director of Education and Mentoring

Heather McArthur

Moderator

Heather McArthur

MD, MPH, FASCO

UT Southwestern Medical Center, Dallas, Texas

Professor, Department of Internal Medicine, Clinical Director, Breast Cancer Program, Komen Distinguished Chair in Clinical Breast Cancer Research

Meeting space has been assigned to provide a symposium supported by AstraZeneca Pharmaceuticals LP, Lilly, and Stemline Therapeutics Inc during the Oncology Nursing Society’s (ONS) 51st Annual Congress, May 13-17, 2026 in San Antonio, TX. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.

    Program Schedule — Central Time

    5:30 PM – 6:00 PM — Registration and Dinner
    6:00 PM – 7:30 PM — Educational Meeting

    MODULE 1: Biology and Current Management of Hormone-Receptor (HR)-Positive Metastatic Breast Cancer (mBC); Clinical Relevance of ESR1 Mutations

    • Incidence, pathophysiology and clinical characteristics of HR-positive mBC
    • Current role of endocrine-based therapies in the management of HR-positive mBC; known mechanisms of resistance to hormonal therapy
    • Prevalence of ESR1 mutations in HR-positive, HER2-negative mBC; relevance of prior therapeutic exposure
    • Optimal timing and approach to testing for ESR1 mutations in patients with HR-positive, HER2-negative mBC
    • Role of oncology nurses in facilitating assessment for ESR1 status in patients with HR-positive, HER2-negative mBC and in helping them understand the implications of results

    MODULE 2: Current Role of Oral Selective Estrogen Receptor Degraders (SERDs) in Therapy for HR-Positive mBC

    • Mechanistic similarities and differences between fulvestrant and the various available and investigational oral SERDs; implications for efficacy and tolerability
    • Published efficacy outcomes with elacestrant for patients with progressive HR-positive, HER2-negative mBC
    • Major findings documenting the efficacy of imlunestrant monotherapy for patients with pretreated HR-positive, HER2-negative mBC
    • FDA approvals of elacestrant and imlunestrant for patients with previously treated HR-positive, HER2-negative mBC and ESR1 mutations
    • Identification of patients appropriate for treatment with elacestrant or imlunestrant

    MODULE 3: Potential Role of Early Therapeutic Switching from an Aromatase Inhibitor to an Oral SERD After Detection of an Emergent ESR1 Mutation During First-Line Therapy for HR-Positive mBC

    • Early-phase data with camizestrant alone for previously treated HR-positive, HER2-negative advanced breast cancer
    • Biological rationale for and potential benefit of serial ESR1 testing for patients receiving first-line endocrine therapy
    • Design, eligibility criteria and key efficacy and safety findings from the Phase III SERENA-6 study evaluating a switch from an aromatase inhibitor to camizestrant after detection of an emergent ESR1 mutation during first-line therapy for HR-positive, HER2-negative mBC
    • Potential role of serial ESR1 testing and early therapeutic switching for patients found to harbor ESR1 mutations

    MODULE 4: Potential Role of Combination Approaches with Oral SERDs for HR-Positive, HER2-Negative Breast Cancer

    • Biological rationale for combining oral SERDs with other systemic therapies, such as CDK4/6 inhibitors or PI3K/AKT/mTOR inhibitors
    • Efficacy and safety outcomes documented with imlunestrant/abemaciclib for patients with HR-positive, HER2-negative advanced breast cancer with and without ESR1 mutations
    • Recently presented data comparing giredestrant in combination with everolimus to standard endocrine therapy with everolimus for pretreated HR-positive, HER2-negative mBC
    • Potential role of oral SERD-containing combination regimens and identification of patients appropriate for this approach
    • Ongoing assessments of other oral SERD-based strategies for patients with HR-positive breast cancer

    MODULE 5: Tolerability of Currently Approved and Investigational Oral SERDs

    • Spectrum, frequency and severity of common class-effect toxicities, such as gastrointestinal (GI) side effects, musculoskeletal pain, fatigue and myelosuppression, documented with oral SERDs; comparative tolerability of elacestrant and imlunestrant
    • Recommended prophylaxis, monitoring and management of GI toxicities associated with oral SERDs
    • Pathophysiology of hyperlipidemia observed with elacestrant and imlunestrant; optimal lipid-profile monitoring for patients receiving either agent
    • Incidence and severity of anemia and hypocalcemia noted with imlunestrant versus other oral SERDs; appropriate monitoring for and management of laboratory-value abnormalities in patients receiving these agents

    Target Audience
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

    Learning Objectives
    Upon completion of this activity, participants should be able to

    • Appreciate the incidence and clinical implications of ESR1 mutations in endocrine-resistant metastatic breast cancer (mBC), and determine optimal strategies to effectively identify patients harboring these abnormalities.
    • Understand the biological rationale for, mechanism of action of and pharmacologic similarities and differences among available and investigational oral selective estrogen receptor degraders (SERDs).
    • Interrogate published research documenting the efficacy of oral SERD monotherapy in patients with hormone receptor (HR)-positive, HER2-negative mBC with ESR1 mutations who experience disease progression on standard endocrine therapy in combination with a CDK4/6 inhibitor, in order to optimally understand the role of these agents in patient care.
    • Review available research findings with serial ESR1 testing using ctDNA as a means to inform early therapeutic switching for patients with HR-positive mBC receiving CDK4/6 inhibitor-based first-line therapy, and consider the clinical applicability of this novel strategy.
    • Evaluate available clinical trial data with oral SERDs in combination with other systemic therapies, such as CDK4/6 inhibitors or mTOR inhibitors, and consider the potential role of these regimens.
    • Appreciate side effects associated with available and investigational oral SERDs, and use this information to develop supportive management plans for patients receiving this form of therapy.
    • Assess ongoing clinical research evaluating novel applications of oral SERDs for HR-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

    Accreditation Statement
    Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    Credit Designation Statements
    This educational activity for 1.5 contact hours is provided by Research To Practice.

    This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

    Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
    The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/OralSERDsMetastaticBreastCancer/ILNA.

    ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    Credit Form
    To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

    Privacy Policy
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    Unlabeled/Unapproved Uses Notice
    There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

    Content Validation and Disclosures
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Ms Ledezma — Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, Pfizer Inc; Steering Committees: AstraZeneca Pharmaceuticals LP. Dr Marti-Smith — Consulting Agreements: Amplity; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: ASCO Quality Care Symposium, Clinical Care Options, Kaplan, OncLive, Oncology Nursing News. Dr O’Regan — Advisory Committees: Biotheranostics Inc, A Hologic Company; Consulting Agreements: Biotheranostics Inc, A Hologic Company, Gilead Sciences Inc, Lilly, Puma Biotechnology Inc, Regor Pharmaceuticals; Contracted Research: Novartis, Puma Biotechnology Inc; Data and Safety Monitoring Boards/Committees: Gilead Sciences Inc.

    MODERATOR — Dr McArthur — Advisory Committees: Arvinas, AstraZeneca Pharmaceuticals LP, Boston Scientific Corporation, Celcuity, Daiichi Sankyo Inc, Delcath Systems Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc; Consulting Agreements: ALX Oncology.

    RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
    Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

    Supporters
    This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP, Lilly, and Stemline Therapeutics Inc.

    Location
    San Antonio Marriott Rivercenter
    101 Bowie St
    San Antonio, TX 78205
    Hotel Phone: (210) 223-1000

    Meeting Room
    Grand Ballroom A-F (Third Floor)

    Directions
    The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

     

    Registration is now closed.

    Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Optimizing the Use of CDK4/6 Inhibitors in the Management of HR-Positive Breast Cancer

    A Complimentary NCPD Symposium Held During the 51st Annual ONS Congress

    Program Schedule — Central Time

    5:30 AM – 6:00 AM — Registration and Breakfast
    6:00 AM – 7:30 AM — Educational Meeting

    Location

    San Antonio Marriott Rivercenter
    101 Bowie St
    San Antonio, Texas
    Hotel Phone: (210) 223-1000

    Meeting Room

    Grand Ballroom A-F (Third Floor)

    No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.

    Faculty

    Kelly Fischer

    Faculty

    Kelly Fischer

    MSN, FNP-BC

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Family Nurse Practitioner

    Marissa Marti-Smith

    Faculty

    Marissa Marti-Smith

    DNP, APRN, AGNP-C, AOCNP

    Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, Texas

    Nurse Practitioner

    Ruth M O'Regan, MD

    Faculty

    Ruth M O'Regan, MD

    University of Rochester Medical Center, Rochester, New York

    Charles A Dewey Professor of Medicine and Oncology, Chair, Department of Medicine,

    Strong Memorial Hospital, Rochester, New York

    Physician-in-Chief

    Wilmot Cancer Institute, Rochester, New York

    Associate Director of Education and Mentoring

    Rita Nanda

    Moderator

    Rita Nanda

    MD

    The University of Chicago, Chicago, Illinois

    Director, Breast Oncology, Associate Professor of Medicine, Section of Hematology/Oncology

    Meeting space has been assigned to provide a symposium supported by Lilly and Novartis during the Oncology Nursing Society’s (ONS) 51st Annual Congress, May 13-17, 2026 in San Antonio, TX. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.

      Program Schedule — Central Time
      5:30 AM – 6:00 AM — Registration and Breakfast
      6:00 AM – 7:30 AM — Educational Meeting

      MODULE 1: Appropriate Risk Assessment for Patients with Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer; Rationale for the Use of CDK4/6 Inhibitors for Those at High Risk for Recurrence

      • Clinicopathologic factors (eg, age, tumor size and grade, nodal involvement) affecting the risk of recurrence for patients with HR-positive, HER2-negative localized breast cancer
      • Long-term outcomes achieved with standard adjuvant endocrine therapy with or without chemotherapy for patients with HR-positive, HER2-negative localized breast cancer, including those at high risk for recurrence
      • Mechanism of antitumor activity of CDK4/6 inhibitors; similarities and differences among available agents in this class
      • Rationale for the addition of CDK4/6 inhibitors to standard adjuvant endocrine therapy for patients with high-risk, HR-positive, HER2-negative localized breast cancer

      MODULE 2: Role of Adjuvant CDK4/6 Inhibitor Therapy for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer

      • Extended follow-up, including recently published overall survival outcomes, with the addition of abemaciclib to standard adjuvant hormonal therapy for patients with high-risk, HR-positive, HER2-negative localized breast cancer
      • Five-year outcomes with ribociclib and endocrine therapy compared to endocrine therapy alone as adjuvant treatment for high-risk, HR-positive, HER2-negative localized breast cancer
      • FDA-approved indications and identification of appropriate candidates for adjuvant abemaciclib and ribociclib

      MODULE 3: CDK4/6 Inhibitors for HR-Positive Metastatic Breast Cancer (mBC)

      • Long-term follow-up data with abemaciclib, palbociclib and ribociclib for patients with HR-positive mBC
      • Factors affecting the selection of a CDK4/6 inhibitor and an endocrine partner for premenopausal and postmenopausal patients
      • Role of CDK4/6 inhibitors in treatment for unique patient populations, such as those with aggressive visceral disease and those with CNS metastases
      • Available data on the utility of continuing CDK4/6 inhibitors beyond progression or rechallenge in later lines of therapy; current role of this strategy in clinical practice

      MODULE 4: Cytopenias Associated with CDK4/6 Inhibitors

      • Similarities and differences in the tolerability profiles of abemaciclib, palbociclib and ribociclib; spectrum and frequency of commonly occurring class-effect toxicities, such as cytopenias, gastrointestinal (GI) events and fatigue
      • Appropriate monitoring of complete blood counts during CDK4/6 inhibitor therapy
      • Thresholds for dose modification, treatment interruption and treatment discontinuation for patients experiencing cytopenias on CDK4/6 inhibitor therapy

      MODULE 5: GI Adverse Events Documented with CDK4/6 Inhibitors

      • Rates of various GI issues (eg, diarrhea, nausea and vomiting, constipation, abdominal pain) in patients receiving CDK4/6 inhibitor therapy
      • Indications for antidiarrheals and/or antiemetics for patients receiving CDK4/6 inhibitors
      • Role of nutritional counselling and diet modifications in CDK4/6 inhibitor treatment

      MODULE 6: Rarer but Potentially Serious Toxicities Associated with 1 or More CDK4/6 Inhibitors

      • Incidence of interstitial lung disease/pneumonitis associated with CDK4/6 inhibitor therapy; recommended algorithms for monitoring, mitigation and management
      • Frequency and severity of hepatotoxicity documented with CDK4/6 inhibitors; appropriate monitoring of liver function tests before and during treatment
      • Rates of venous thromboembolic events (VTE) reported with CDK4/6 inhibitor therapy; optimal monitoring for signs of VTE and precautionary measures for patients with preexisting risk factors
      • Severe cutaneous adverse reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms) documented with CDK4/6 inhibitors; role of dermatologic consultation in the care of patients with signs or symptoms
      • Incidence of cardiac toxicity with ribociclib; appropriate use of electrocardiogram monitoring before and during therapy

      MODULE 7: Practical Considerations with CDK4/6 Inhibitors

      • Optimal dosing and dose-adjustment strategies with CDK4/6 inhibitors for patients with localized and metastatic breast cancer
      • Recommended duration of CDK4/6 inhibitor therapy in the adjuvant setting
      • Approaches for encouraging and assessing adherence for patients receiving CDK4/6 inhibitor therapy
      • Drug-drug interactions noted with 1 or more CDK4/6 inhibitors

      Target Audience
      This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

      Learning Objectives
      Upon completion of this activity, participants should be able to

      • Discern the mechanism by which the cyclin-dependent kinase (CDK) pathway contributes to breast cancer proliferation and growth, and consider the implications for the management of hormone receptor (HR)-positive disease.
      • Understand how various clinical and biological factors, such as age or menopausal status, tumor size or grade and nodal involvement, affect the risk of disease recurrence, and use this information to personalize the selection of adjuvant systemic therapy for patients with newly diagnosed HR-positive, HER2-negative localized breast cancer.
      • Consider available clinical trial findings with CDK4/6 inhibitors for localized HR-positive, HER2-negative breast cancer, and identify patients for whom adjuvant treatment with one of these agents would be appropriate.
      • Appraise published findings from randomized clinical trials establishing the efficacy and safety of CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer in order to understand the risks, benefits and optimal clinical use of these agents in various patient subgroups.
      • Recognize adverse events and other common side effects associated with different CDK4/6 inhibitors for breast cancer, and tailor therapy for patients with preexisting medical conditions and relevant comorbidities.
      • Develop preventive and emergent strategies to reduce or ameliorate the various toxicities associated with CDK4/6 inhibitors.

      Accreditation Statement
      Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

      Credit Designation Statements
      This educational activity for 1.5 contact hours is provided by Research To Practice.

      This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

      Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
      The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/CDKiHRPositiveBreastCancer/ILNA.

      ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

      Credit Form
      To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

      Privacy Policy
      Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

      Unlabeled/Unapproved Uses Notice
      There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

      Content Validation and Disclosures
      Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

      FACULTY — Ms Fischer has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

      Ms Marti-Smith — Consulting Agreements: Amplity; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: ASCO Quality Care Symposium, Clinical Care Options, Kaplan, OncLive, Oncology Nursing News. Dr O’Regan — Advisory Committees: Biotheranostics Inc, A Hologic Company; Consulting Agreements: Biotheranostics Inc, A Hologic Company, Gilead Sciences Inc, Lilly, Puma Biotechnology Inc, Regor Pharmaceuticals; Contracted Research: Novartis, Puma Biotechnology Inc; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.

      MODERATOR — Dr Nanda — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Exact Sciences Corporation, Gilead Sciences Inc, Lilly, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Summit Therapeutics; Contracted Research: Arvinas, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Relay Therapeutics.

      RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
      Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

      Supporters
      This activity is supported by educational grants from Lilly and Novartis.

      Location
      San Antonio Marriott Rivercenter
      101 Bowie St
      San Antonio, TX 78205
      Hotel Phone: (210) 223-1000

      Meeting Room
      Grand Ballroom A-F (Third Floor)

      Directions
      The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

       

      Registration is now closed.

      The Optimal Implementation of Antibody-Drug Conjugates in the Care of Patients with Cancer

      Accreditation types: 1.75 NCPD

      To play this presentation please log in.

      Don't have an account?

      Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

      Faculty

      Marianne J Davies

      Faculty

      Marianne J Davies

      DNP, ACNP, AOCNP, FAAN

      Yale New Haven Health, New Haven, Connecticut

      Program Manager, Care Signature, Oncology Service Line

      Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut

      Oncology Nurse Practitioner-Senior APP II

      Yale University School of Nursing, New Haven, Connecticut

      Associate Professor

      Edward B Garon

      Faculty

      Edward B Garon

      MD, MS

      David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, Los Angeles, California

      Professor, Director, Thoracic Oncology Program, Director, Signal Transduction and Therapeutics Research Program

      Marissa Marti-Smith

      Faculty

      Marissa Marti-Smith

      DNP, APRN, AGNP-C, AOCNP

      Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, Texas

      Nurse Practitioner

      Tiffany A Traina

      Faculty

      Tiffany A Traina

      MD, FASCO

      Memorial Sloan Kettering Cancer Center, New York, New York

      Vice Chair, Department of Medicine, Section Head, Triple-Negative Breast Cancer Clinical Research Program, Associate Attending Physician, Breast Medicine Service

      Weill Cornell Medical College, New York, New York

      Associate Professor

      TARGET AUDIENCE
      This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.

      PURPOSE STATEMENT
      By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with cancer.

      LEARNING OBJECTIVES

      • Consider the scientific justification for the use of antibody-drug conjugates (ADCs) as a therapeutic approach for patients with various tumor types, and recall the targets, structural components and mechanisms of activity of different clinically available and investigational agents in this class.
      • Appraise available clinical research data with novel ADCs for various cancers, and consider the current and potential role of these approaches in routine clinical care.
      • Appreciate the pathophysiology and severity of common and rare toxicities associated with ADCs employed in the treatment of different tumor types.
      • Understand the incidence of toxicities observed in pivotal trials evaluating novel ADCs, and educate patients about to commence therapy with these approaches regarding the potential development of these adverse events and what to do if they are suspected.
      • Recall strategies commonly employed to identify, manage and mitigate resultant toxicities of anticancer treatment with ADCs, and use this information to appropriately intervene for patients in whom these side effects are suspected or diagnosed.
      • Understand the role of multidisciplinary specialists such as cardiologists, ophthalmologists and other medical professionals in the diagnosis and management of ADC-associated toxicities, and effectively educate patients regarding the potential need for and importance of specialty referral.

      ACCREDITATION STATEMENT
      Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

      CREDIT DESIGNATION STATEMENT
      Video Program: This educational activity for 1.75 contact hours is provided by RTP during the period of April 2025 to April 2026.

      This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.

      ONCC/ILNA CERTIFICATION INFORMATION
      The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2025/ADCs/ILNA.

      ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

      PRIVACY POLICY
      Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

      FOR SUCCESSFUL COMPLETION
      Video Program: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2025/ADCsPanTumor/Video/NCPD.

      CONTENT VALIDATION AND DISCLOSURES
      Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

      FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

      Marianne J Davies, DNP, ACNP, AOCNP, FAAN
      Program Manager, Care Signature
      Oncology Service Line, Yale New Haven Health
      Oncology Nurse Practitioner-Senior APP II
      Yale Cancer Center
      Smilow Cancer Hospital at Yale New Haven
      Associate Professor
      Yale University School of Nursing
      New Haven, Connecticut

      No relevant conflicts of interest to disclose.

      Edward B Garon, MD, MS
      Professor
      Director, Thoracic Oncology Program
      Director, Signal Transduction and Therapeutics Research Program
      David Geffen School of Medicine at UCLA
      Jonsson Comprehensive Cancer Center
      Los Angeles, California

      Advisory Committees and Consulting Agreements: AbbVie Inc, Arcus Biosciences, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, Atreca, Black Diamond Therapeutics Inc, BridgeBio, Bristol Myers Squibb, EMD Serono Inc, Gilead Sciences Inc, Hookipa Pharma Inc, I-Mab Biopharma, LianBio, Lilly, Merck, Merus, Novartis, Nuvalent, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Sensei Biotherapeutics, Strata Oncology, Sumitomo Dainippon Pharma Oncology Inc, Summit Therapeutics, Synthekine; Contracted Research: ABL Bio, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics Inc, Novartis, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Synthekine, TILT Biotherapeutics; Sponsored Independent Medical Education: Daiichi Sankyo Inc; Travel: A2 Bio, Novartis.

      Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNP
      Nurse Practitioner
      Texas Oncology-Baylor Charles A Sammons Cancer Center
      Dallas, Texas

      Speakers Bureaus: Biotheranostics Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: ASCO Advantage, Clinical Education Alliance.

      Tiffany A Traina, MD, FASCO
      Vice Chair, Department of Medicine
      Section Head, Triple-Negative Breast Cancer Clinical Research Program
      Associate Attending Physician
      Breast Medicine Service
      Memorial Sloan Kettering Cancer Center
      Associate Professor
      Weill Cornell Medical College
      New York, New York

      Advisory Committees and Consulting Agreements: Aktis Oncology, AstraZeneca Pharmaceuticals LP, BioNTech SE, Daiichi Sankyo Inc, Ellipses Pharma, Exact Sciences Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Merck, Pfizer Inc, Stemline Therapeutics Inc, TerSera Therapeutics LLC, Veracyte Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, BioNTech SE, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Pfizer Inc.

      MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

      RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

      These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

      These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.

      Release date: April 2025
      Expiration date: April 2026

      There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

      Dr Traina

      Module 2: Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Metastatic Breast Cancer (mBC) with and without Brain Metastases

      André F et al. A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases. Ann Oncol 2024;35(12):1169-80. Abstract

      Cortés J et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: Long-term survival analysis of the DESTINY-Breast03 trial. Nat Med 2024;30(8):2208-15. Abstract

      Curigliano G et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): Final overall survival analysis. Ann Oncol 2022;33(3):321-9. Abstract

      Hamilton EP et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03. ASCO 2024;Abstract 1025.

      Harbeck N et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: A phase 3b/4 trial. Nat Med 2024;30(12):3717-27. Abstract

      Hurvitz SA et al. A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03. ESMO 2023;Abstract 377O.

      Murthy RK et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 2020;382(7):597-609. Abstract

      Saura C et al. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: Updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol 2024;35(3):302-7. Abstract

      Swain SM et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2020;21(4):519-30. Abstract

       

      Module 3: Role of ADCs for Patients with ER-Positive mBC

      Bardia A et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med 2024;391(22):2110-22. Abstract

      Bardia A et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial. ESMO 2023;Abstract LBA11.

      Bardia A et al. Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01. San Antonio Breast Cancer Symposium 2023;Abstract GS02-01.

      Curigliano G et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). ASCO 2024;Abstract LBA1000.

      Huppert LA et al. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies. ASCO 2024;Abstract 1083.

      Modi S et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study. ESMO 2023;Abstract 376O.

      Rugo HS et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial. Lancet 2023;402(10411):1423-33. Abstract

      Rugo HS et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. ASCO 2022;Abstract LBA1001.

      Tolaney SM et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). ASCO 2023;Abstract 1003.

       

      Ms Marti-Smith

      Module 2: Overview of Antibody-Drug Conjugates (ADCs)

      Rugo HS et al. Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer. JCO Oncol Pract 2023;19(8):539-46. Abstract

       

      Module 3: Role of ADCs for Patients with ER-Positive mBC

      Spring LM et al. Sacituzumab govitecan for metastatic triple-negative breast cancer: Clinical overview and management of potential toxicities. Oncologist 2021;26(10):827-34. Abstract

       

      Dr Garon

      Module 4: T-DXd in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with HER2 Alterations

      Goto K et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: Primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol 2023;41(31):4852-63. Abstract

      Janne PA et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02. ASCO 2024;Abstract 8543.

      Li BT et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 2022;386(3):241-51. Abstract

      Odintsov I et al. Prevalence and therapeutic targeting of high-level ERBB2 amplification in NSCLC. J Thorac Oncol 2024;19(5):732-48. Abstract

      Planchard D et al. Trastuzumab deruxtecan monotherapy in pretreated HER2-overexpressing nonsquamous non-small cell lung cancer: DESTINY-Lung03 part 1. WCLC 2024;Abstract OA16.05.

      Uzunparmak B et al. HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol 2023;34(11):1035-46. Abstract

      Waliany S et al. Real-world prevalence, treatment patterns, and outcomes for patients with HER2 (ERBB2)-mutant metastatic non-small cell lung cancer, from a US-based clinico-genomic database. Cancer Med 2024;13(24):e70272. Abstract

       

      Module 5: Emerging Role of ADCs for Patients with Progressive EGFR-Mutant NSCLC

      Ahn M et al. Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01. ESMO 2023;Abstract LBA12.

      Krop IE et al. Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). ASCO 2022;Abstract 1002.

      Paz-Ares L et al. TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs). ESMO 2023;Abstract 1314MO.

      Sands J et al. Datopotamab deruxtecan vs docetaxel in patients with non-small cell lung cancer: Final overall survival from TROPION-Lung01. WCLC 2024;Abstract OA08.03.

      Yu HA et al. HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol 2023;41(35):5363-75. Abstract

       

      Ms Davies

      Module 4: T-DXd in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with HER2 Alterations

      Tarantino P, Tolaney SM. Detecting and managing T-DXd-related interstitial lung disease: The five “S” rules. JCO Oncol Pract 2023;19(8):526-7. Abstract

      Tarantino P et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: A review. JAMA Oncol 2021;7(12):1873-81. Abstract

       

      Module 5: Emerging Role of ADCs for Patients with Progressive EGFR-Mutant NSCLC

      Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract

      • for-nurses